← All trials
NCT05351671
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 23, 2022
- Primary completion
- Nov 10, 2022
- Completion date
- Nov 15, 2022
- First posted
- Apr 28, 2022
- Last posted
- May 31, 2022
- Enrollment
- 48
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ReAlta Life Sciences, Inc.Lead sponsor
- FGK Clinical Research GmbHCollaborator
- ReAlta Life Sciences, Inc.Study chair
- ReAlta Life Sciences, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.